Zealand Pharma agreed to use Generate Biomedicines’ AI technology to develop protein-based treatments for obesity and other metabolic diseases. The Danish company will spend $30 million upfront for two initial programs, with the partnership designed to accelerate discovery using AI-driven protein design. The deal arrives amid intense competition in obesity pharmacology, where companies are looking to differentiate pipelines beyond GLP-1-based approaches and to shorten early development timelines. For biotech investors and pipeline planners, the agreement signals continued scaling of AI-enabled platform collaborations aimed at feeding clinical-stage obesity programs faster and with more targeted mechanisms.